Mobile Health-Supported HIV Self-Testing Strategy Among Urban Refugee and Displaced Youth in Kampala, Uganda: Protocol for a Cluster Randomized Trial (Tushirikiane, Supporting Each Other).
HIV testing
Uganda
adolescents and youth
implementation research
mobile health
refugee
Journal
JMIR research protocols
ISSN: 1929-0748
Titre abrégé: JMIR Res Protoc
Pays: Canada
ID NLM: 101599504
Informations de publication
Date de publication:
02 Feb 2021
02 Feb 2021
Historique:
received:
01
12
2020
accepted:
18
12
2020
revised:
14
12
2020
entrez:
2
2
2021
pubmed:
3
2
2021
medline:
3
2
2021
Statut:
epublish
Résumé
HIV is the leading cause of mortality among youth in sub-Saharan Africa. Uganda hosts over 1.43 million refugees, and more than 83,000 live in Kampala, largely in informal settlements. There is limited information about HIV testing uptake and preferences among urban refugee and displaced youth. HIV self-testing is a promising method for increasing testing uptake. Further, mobile health (mHealth) interventions have been effective in increasing HIV testing uptake and could be particularly useful among youth. This study aims to evaluate the feasibility and effectiveness of two HIV self-testing implementation strategies (HIV self-testing intervention alone and HIV self-testing combined with an mHealth intervention) in comparison with the HIV testing standard of care in terms of HIV testing outcomes among refugee/displaced youth aged 16 to 24 years in Kampala, Uganda. A three-arm cluster randomized controlled trial will be implemented across five informal settlements grouped into three sites, based on proximity, and randomization will be performed with a 1:1:1 method. Approximately 450 adolescents (150 per cluster) will be enrolled and followed for 12 months. Data will be collected at the following three time points: baseline enrollment, 8 months after enrollment, and 12 months after enrollment. Primary outcomes (HIV testing frequency, HIV status knowledge, linkage to confirmatory testing, and linkage to HIV care) and secondary outcomes (depression, condom use efficacy, consistent condom use, sexual relationship power, HIV stigma, and adolescent sexual and reproductive health stigma) will be evaluated. The study has been conducted in accordance with CONSORT (Consolidated Standards of Reporting Trials) guidelines. The study has received ethical approval from the University of Toronto (June 14, 2019), Mildmay Uganda (November 11, 2019), and the Uganda National Council for Science and Technology (August 3, 2020). The Tushirikiane trial launched in February 2020, recruiting a total of 452 participants. Data collection was paused for 8 months due to COVID-19. Data collection for wave 2 resumed in November 2020, and as of December 10, 2020, a total of 295 participants have been followed-up. The third, and final, wave of data collection will be conducted between February and March 2021. This study will contribute to the knowledge of differentiated HIV testing implementation strategies for urban refugee and displaced youth living in informal settlements. We will share the findings in peer-reviewed manuscripts and conference presentations. ClinicalTrials.gov NCT04504097; https://clinicaltrials.gov/ct2/show/NCT04504097. DERR1-10.2196/26192.
Sections du résumé
BACKGROUND
BACKGROUND
HIV is the leading cause of mortality among youth in sub-Saharan Africa. Uganda hosts over 1.43 million refugees, and more than 83,000 live in Kampala, largely in informal settlements. There is limited information about HIV testing uptake and preferences among urban refugee and displaced youth. HIV self-testing is a promising method for increasing testing uptake. Further, mobile health (mHealth) interventions have been effective in increasing HIV testing uptake and could be particularly useful among youth.
OBJECTIVE
OBJECTIVE
This study aims to evaluate the feasibility and effectiveness of two HIV self-testing implementation strategies (HIV self-testing intervention alone and HIV self-testing combined with an mHealth intervention) in comparison with the HIV testing standard of care in terms of HIV testing outcomes among refugee/displaced youth aged 16 to 24 years in Kampala, Uganda.
METHODS
METHODS
A three-arm cluster randomized controlled trial will be implemented across five informal settlements grouped into three sites, based on proximity, and randomization will be performed with a 1:1:1 method. Approximately 450 adolescents (150 per cluster) will be enrolled and followed for 12 months. Data will be collected at the following three time points: baseline enrollment, 8 months after enrollment, and 12 months after enrollment. Primary outcomes (HIV testing frequency, HIV status knowledge, linkage to confirmatory testing, and linkage to HIV care) and secondary outcomes (depression, condom use efficacy, consistent condom use, sexual relationship power, HIV stigma, and adolescent sexual and reproductive health stigma) will be evaluated.
RESULTS
RESULTS
The study has been conducted in accordance with CONSORT (Consolidated Standards of Reporting Trials) guidelines. The study has received ethical approval from the University of Toronto (June 14, 2019), Mildmay Uganda (November 11, 2019), and the Uganda National Council for Science and Technology (August 3, 2020). The Tushirikiane trial launched in February 2020, recruiting a total of 452 participants. Data collection was paused for 8 months due to COVID-19. Data collection for wave 2 resumed in November 2020, and as of December 10, 2020, a total of 295 participants have been followed-up. The third, and final, wave of data collection will be conducted between February and March 2021.
CONCLUSIONS
CONCLUSIONS
This study will contribute to the knowledge of differentiated HIV testing implementation strategies for urban refugee and displaced youth living in informal settlements. We will share the findings in peer-reviewed manuscripts and conference presentations.
TRIAL REGISTRATION
BACKGROUND
ClinicalTrials.gov NCT04504097; https://clinicaltrials.gov/ct2/show/NCT04504097.
INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID)
UNASSIGNED
DERR1-10.2196/26192.
Identifiants
pubmed: 33528378
pii: v10i2e26192
doi: 10.2196/26192
pmc: PMC7886618
doi:
Banques de données
ClinicalTrials.gov
['NCT04504097']
Types de publication
Journal Article
Langues
eng
Pagination
e26192Subventions
Organisme : NIMH NIH HHS
ID : R25 MH118935
Pays : United States
Informations de copyright
©Carmen Logie, Moses Okumu, Robert Hakiza, Daniel Kibuuka Musoke, Isha Berry, Simon Mwima, Peter Kyambadde, Uwase Mimy Kiera, Miranda Loutet, Stella Neema, Katie Newby, Clara McNamee, Stefan D Baral, Richard Lester, Joshua Musinguzi, Lawrence Mbuagbaw. Originally published in JMIR Research Protocols (http://www.researchprotocols.org), 02.02.2021.
Références
Int J Environ Res Public Health. 2012 Feb;9(2):596-609
pubmed: 22470312
Sex Reprod Health Matters. 2019 Dec;27(3):86-106
pubmed: 31880507
Lancet. 2011 Jul 16;378(9787):269-78
pubmed: 21763938
Lancet HIV. 2016 Jul;3(7):e318-22
pubmed: 27365206
PLoS One. 2012;7(12):e46909
pubmed: 23236345
J Int AIDS Soc. 2015 Feb 26;18(2 Suppl 1):19433
pubmed: 25724506
AIDS Behav. 2014 Jul;18 Suppl 4:S450-8
pubmed: 24957978
J Int AIDS Soc. 2017 Jan 01;19(1):21111
pubmed: 28406597
BMC Int Health Hum Rights. 2013 Apr 23;13:22
pubmed: 23617404
AIDS Behav. 2014 Dec;18(12):2359-65
pubmed: 24146070
J Sex Res. 2018 Jan;55(1):60-72
pubmed: 28266874
J Int AIDS Soc. 2017 May 15;20(1):21594
pubmed: 28530049
J Med Internet Res. 2012 Feb 01;14(1):e20
pubmed: 22297093
Lancet. 2007 Jun 30;369(9580):2187-2195
pubmed: 17604801
BMJ Open. 2015 Dec 18;5(12):e008226
pubmed: 26685020
J Int AIDS Soc. 2016 Nov 17;19(1):21263
pubmed: 27863535
BMJ. 2019 Apr 1;365:l1083
pubmed: 30936067
Soc Sci Med. 2008 Oct;67(8):1225-35
pubmed: 18599171
Lancet Public Health. 2017 Apr;2(4):e182-e190
pubmed: 29253450
J Int AIDS Soc. 2014 Aug 01;17:19032
pubmed: 25095831
PLoS One. 2020 Jul 20;15(7):e0236316
pubmed: 32687519
Lancet. 2016 Jun 11;387(10036):2383-401
pubmed: 27174305
J Am Coll Health. 1991 Mar;39(5):219-25
pubmed: 1783705
BMJ Glob Health. 2018 May 3;3(2):e000682
pubmed: 29736272
Lancet HIV. 2016 Jul;3(7):e297-306
pubmed: 27365204
PLoS One. 2018 Jul 6;13(7):e0199300
pubmed: 29980147
AIDS Behav. 2019 May;23(5):1225-1239
pubmed: 30652205
Glob Health Promot. 2013 Mar;20(1 Suppl):26-32
pubmed: 23549699
Lancet. 2017 Feb 4;389(10068):559-570
pubmed: 27760702
Glob Health Sci Pract. 2013 Aug 06;1(2):160-71
pubmed: 25276529
PLoS Med. 2015 Sep 08;12(9):e1001873
pubmed: 26348035
BMC Health Serv Res. 2008 Oct 09;8:210
pubmed: 18844998
Lancet Public Health. 2018 Mar;3(3):e143-e152
pubmed: 29361433
PLoS One. 2020 Jan 23;15(1):e0227741
pubmed: 31971991
J Gen Intern Med. 2001 Sep;16(9):606-13
pubmed: 11556941
Curr Opin HIV AIDS. 2017 Sep;12(5):425-431
pubmed: 28617712
Lancet. 2010 Nov 27;376(9755):1838-45
pubmed: 21071074